New law directs HHS to consider comparative effectiveness information as it approaches price negotiations with manufacturers. But it’s not clear what that means and stakeholders will watch for greater clarity from implementing regulations. ICER’s Steve Pearson weighs in on what they might say.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?